$750 | Single User
$1500 | Site License
$2250 | Global License

Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update [Report Updated: 27-12-2018]

Published by Global Data: 27 Dec 2018 | 228685 | In Stock

Introduction

Summary

Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Guardant Health Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update [Report Updated: 27-12-2018]

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 3

    Guardant Health Inc Company Overview 4

    Guardant Health Inc Company Snapshot 4

    Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4

    Guardant Health Inc – Pipeline Analysis Overview 7

    Guardant Health Inc - Key Facts 7

    Guardant Health Inc - Major Products and Services 8

    Guardant Health Inc Pipeline Products by Development Stage 9

    Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

    Guardant Health Inc Pipeline Products Overview 13

    Anti-RSP03 Antibody Based Blood Test 13

    Anti-RSP03 Antibody Based Blood Test Product Overview 13

    Gene-Based Test - Lung Cancer 14

    Gene-Based Test - Lung Cancer Product Overview 14

    GUARDANT360 15

    GUARDANT360 Product Overview 15

    GUARDANT360 Clinical Trial 16

    Guardant360 CDx Test - Tepotinib 18

    Guardant360 CDx Test - Tepotinib Product Overview 18

    Guardant360 Companion Diagnostic Assay - Glesatinib 19

    Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview 19

    Guardant Health Inc - Key Competitors 20

    Guardant Health Inc - Key Employees 21

    Guardant Health Inc - Locations And Subsidiaries 22

    Head Office 22

    Recent Developments 23

    Guardant Health Inc, Recent Developments 23

    Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients 23

    Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit 23

    Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications 23

    Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer 24

    May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications 24

    Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison 25

    Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay 25

    Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients 26

    Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood 26

    Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial 27

    Appendix 28

    Methodology 28

    About GlobalData 31

    Contact Us 31

    Disclaimer 31

List Of Tables
in Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update [Report Updated: 27-12-2018]

List of Tables

Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4

Guardant Health Inc Pipeline Products by Equipment Type 5

Guardant Health Inc Pipeline Products by Indication 6

Guardant Health Inc Ongoing Clinical Trials by Trial Status 6

Guardant Health Inc, Key Facts 7

Guardant Health Inc, Major Products and Services 8

Guardant Health Inc Number of Pipeline Products by Development Stage 9

Guardant Health Inc Pipeline Products Summary by Development Stage 10

Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

Guardant Health Inc Ongoing Clinical Trials Summary 12

Anti-RSP03 Antibody Based Blood Test - Product Status 13

Anti-RSP03 Antibody Based Blood Test - Product Description 13

Gene-Based Test - Lung Cancer - Product Status 14

Gene-Based Test - Lung Cancer - Product Description 14

GUARDANT360 - Product Status 15

GUARDANT360 - Product Description 15

GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies 16

GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection 16

GUARDANT360 - Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer 16

GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) 16

GUARDANT360 - Noninvasive versus Invasive Lung Evaluation 17

GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial 17

Guardant360 CDx Test - Tepotinib - Product Status 18

Guardant360 CDx Test - Tepotinib - Product Description 18

Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status 19

Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description 19

Guardant Health Inc, Key Employees 21

Glossary 30

List Of Figures, Charts and Diagrams
in Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update [Report Updated: 27-12-2018]

List of Figures

Guardant Health Inc Pipeline Products by Equipment Type 5

Guardant Health Inc Pipeline Products by Development Stage 9

Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

Additional Details

Publisher

Global Data

Publisher Information

Reference

228685 | GDME509615PD

Number of Pages

31

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Guardant Health Inc - Medical Equipment - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics that offers commer...
11 May 2018 by Global Data USD $250 More Info
Guardant Health Inc - Medical Equipment - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics that offers commer...
08 Feb 2018 by Global Data USD $250 More Info
Guardant Health Inc - Medical Equipment - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics that offers commer...
12 Oct 2017 by Global Data USD $250 More Info
Guardant Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics that offers commer...
12 Oct 2017 by Global Data USD $250 More Info
Guardant Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) offers non-invasive cancer diagnostics and commercializ...
28 Aug 2017 by Global Data USD $250 More Info
Guardant Health Inc - Medical Equipment - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) offers non-invasive cancer diagnostics and commercializ...
12 Jul 2017 by Global Data USD $250 More Info
Guardant Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) offers non-invasive cancer diagnostics and commercializ...
26 Apr 2017 by Global Data USD $250 More Info
Guardant Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) offers non-invasive cancer diagnostics and commercializ...
20 Mar 2017 by Global Data USD $250 More Info
Guardant Health Inc - Medical Equipment - Deals and Alliances Profile
SummaryGuardant Health Inc (Guardant Health) offers non-invasive cancer diagnostics and commercializ...
24 Jan 2017 by Global Data USD $250 More Info

This report is published by Global Data

Download Free Report Summary PDF

Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update [Report Updated: 27-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data